A Phase 2a Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NLY01, a PEGylated Exenatide, when Administered as a Single Dose in Subjects with Type 2 Diabetes - Trial 2019-000398-21
Access comprehensive clinical trial information for 2019-000398-21 through Pure Global AI's free database. This phase not specified trial is sponsored by Neuraly, Inc. and is currently Completed. The study focuses on Type 2 Diabetes mellitus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2019-000398-21
Completed
Trial Details
EU Clinical Trials Register • 2019-000398-21
A Phase 2a Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NLY01, a PEGylated Exenatide, when Administered as a Single Dose in Subjects with Type 2 Diabetes
Study Focus
Sponsor & Location
Neuraly, Inc.
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
- Known or suspected hypersensitivity to the IMP or related products
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications
Data Source
EU Clinical Trials Register
2019-000398-21
Non-Device Trial